PLA2G7 and metabolic dysfunction-associated steatotic liver disease: Additionally, both positive and negative associations between plasma Lp‐PLA2 levels and nonalcoholic fatty liver disease (NAFLD) were demonstrated in epidemiological studies, and Lp‐PLA2 seemingly protected subjects against the initiation and progression of NAFLD.226, 227 However, considering the observation that lysoPC administration could induce hepatitis in vivo, contrary to the protective role of Lp‐PLA2,228 further investigations using a longitudinal design is necessary to identify the cause.